Semaglutide for the treatment of MASH: reaching into the ESSENCE of cardio-metabolic health?

Interim analysis at 72 weeks demonstrated that semaglutide substantially improved liver histology in patients with biopsy-proven MASH and moderate-to-advanced fibrosis.

• Semaglutide effectively resolved steatohepatitis and improved liver fibrosis compared to placebo.
• Accelerated approval for semaglutide (Wegovy) was granted by the U.S. Food and Drug Administration for adults with noncirrhotic MASH and stage 2 or 3 fibrosis.
• Notable improvements in body weight, insulin sensitivity, and inflammatory markers were observed alongside hepatic benefits.
• The clinical relevance of these findings remains uncertain until long-term outcomes for liver complications and overall cardio-renal risk are established.

AI simplified